Here are three insights:
1. Along with postponing the financial results, the medical device manufacture also rescheduled the following conference call, scheduled for Nov. 9.
2. Xtant plans to release its third quarter 2017 financial results by Nov. 20 in conjunction with the filing of its 10-Q.
3. Xtant develops, manufactures and markets regenerative medicine products, as well as orthopedic and neurological devices. Earlier this month, the company entered into a distribution agreement with Curasan, adding synthetic scaffolds to its biologics portfolio.
More articles on devices and implants:
Stryker, Smith & Nephew & more: 9 device company mergers, acquisitions and agreements
Global interventional spine devices market to expand at10.5% CAGR through 2021 — 4 notes
Mazor reports Q3 revenue at $17.2M, $3.7M net loss: 6 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.